Earnings

ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate

Aug 12, 2026 · 04:17 PM ET· updated 49m ago

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 16.67 percent decrease over losses of $(0.90) per share

Why It Matters

ArriVent lost more money per share than experts thought it would, and its losses are getting bigger over time. When a company loses more money than people expected, it can make investors feel less confident about whether the company is heading in the right direction.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

AVBP31.48

+0.09 (+0.29%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.